Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
暂无分享,去创建一个
Sue Healey | John L Hopper | Georgia Chenevix-Trench | Sean V Tavtigian | Sunil R Lakhani | J. Hopper | A. Spurdle | S. Lakhani | G. Chenevix-Trench | S. Tavtigian | Melissa A. Brown | S. Parry | D. Goldgar | R. Brinkworth | S. Healey | Amanda B Spurdle | David E Goldgar | Melissa A Brown | Suzanne Parry | Davit Babikyan | Ross Brinkworth | Leonard M Da Silva | D. Babikyan | L. D. Da Silva
[1] L. Bégin,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.
[2] L. Shulman,et al. A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition Genes , 2008 .
[3] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.
[5] J. Benítez,et al. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information , 2007, Human mutation.
[6] B. Ward,et al. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. , 2005, Cancer research.
[7] M. Stratton,et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. , 2000, Cancer research.
[8] Douglas F Easton,et al. A full-likelihood method for the evaluation of causality of sequence variants from family data. , 2003, American journal of human genetics.
[9] J. Glover,et al. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1 , 2001, Nature Structural Biology.
[10] William D. Foulkes,et al. Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .
[11] John A Tainer,et al. Full‐length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly and control by BRCA2 , 2003, The EMBO journal.
[12] M. Stratton,et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] M. King,et al. BRCA1 RING Domain Cancer-predisposing Mutations , 2001, The Journal of Biological Chemistry.
[14] A. Zharkikh,et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral , 2005, Journal of Medical Genetics.
[15] F. Couch,et al. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? , 2007, Breast Cancer Research.
[16] F. Couch,et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. , 2005, Cancer research.
[17] L. Bégin,et al. The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.
[18] Julian Peto,et al. Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.
[19] A. Meindl,et al. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population , 2002, International journal of cancer.
[20] J. Benítez,et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas , 2006, Journal of Clinical Pathology.
[21] M. Stratton,et al. Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families , 1999, British Journal of Cancer.
[22] J. Hopper,et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. , 2006, Cancer research.
[23] F. Couch,et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.
[24] M. Stratton,et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.
[25] John L Hopper,et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource , 2006, Breast Cancer Research.